Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Deferred Taxes: 2021-2024

Historic Deferred Taxes for Collegium Pharmaceutical (COLL) over the last 4 years, with Dec 2024 value amounting to -$26.8 million.

  • Collegium Pharmaceutical's Deferred Taxes fell 38.92% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.7 million, marking a year-over-year decrease of 51.45%. This contributed to the annual value of -$26.8 million for FY2024, which is 1145.42% down from last year.
  • Collegium Pharmaceutical's Deferred Taxes amounted to -$26.8 million in FY2024, which was down 1,145.42% from -$2.2 million recorded in FY2023.
  • Over the past 5 years, Collegium Pharmaceutical's Deferred Taxes peaked at -$2.2 million during FY2023, and registered a low of -$78.0 million during FY2021.
  • For the 3-year period, Collegium Pharmaceutical's Deferred Taxes averaged around -$12.5 million, with its median value being -$8.4 million (2022).
  • Its Deferred Taxes has fluctuated over the past 5 years, first spiked by 89.25% in 2022, then plummeted by 1,145.42% in 2024.
  • Yearly analysis of 4 years shows Collegium Pharmaceutical's Deferred Taxes stood at -$78.0 million in 2021, then soared by 89.25% to -$8.4 million in 2022, then soared by 74.34% to -$2.2 million in 2023, then slumped by 1,145.42% to -$26.8 million in 2024.